Patrick Chaltin

He is a qualified European Patent Attorney and was previously active as IP manager at the IP unit of KU Leuven Research & Development, which he joined in 2002 and where he was responsible for the management of the IP created by KU Leuven within the pharmaceutical field, especially by the Rega Institute for Medical Research. He is member of the Board of Directors of Cytura Therapeutics and previously of Okapi Sciences until its acquisition by Aratana. During 2003, he was also member of the deal flow committee of Capricorn Venture Partners for the analysis of new investment opportunities. He studied Pharmaceutical Sciences and obtained a Ph.D. in this field at the laboratory of Medicinal Chemistry of KU Leuven. Patrick Chaltin is co-author of several peer-reviewed scientific publications and is inventor on multiple patent applications.